Hexarelin for growth hormone: hype vs. what studies show

What did @official.justin.bucki actually say?

The creator described hexarelin as a GHRP-family peptide that is "even more potent than GHRP-6," warned that it stimulates ghrelin-driven hunger similar to GHRP-6, and suggested it works best as an injectable rather than oral form. He also recommended pairing hexarelin with a GHRH peptide like CJC-1295 or sermorelin to get both a release and a production effect from the pituitary. He was skeptical of oral formulations as a replacement for MK-677, and closed with optimism that peptides are not disappearing from the market given FDA scrutiny.

Credit where it is due: the framing around combining a GHRP with a GHRH is mechanistically sound and not something most TikTok peptide creators bother to explain. The ghrelin point is also real, not invented. But there are some details worth examining more carefully before anyone acts on this.

Does the science back this up?

The potency claim holds up reasonably well. The ghrelin-hunger connection is accurate but slightly oversimplified. The oral bioavailability skepticism is probably correct, though the data is thin.

Hexarelin (hexarelin acetate) is a synthetic six-amino-acid GHRP that binds both the GHS-R1a receptor and, importantly, the CD36 scavenger receptor, which gives it some cardiovascular signaling activity not shared by GHRP-6. Multiple studies confirm it produces a stronger GH pulse than GHRP-6 at equivalent doses. Popovic et al. (1994, Journal of Clinical Endocrinology and Metabolism) showed hexarelin produced significantly greater GH release in healthy adults compared to GHRP-6. The ghrelin-hunger mechanism the creator describes is real: GHRP-6 and hexarelin both act on ghrelin receptors in the gut, and orexigenic effects are well-documented (Wren et al., 2001, Journal of Clinical Endocrinology and Metabolism). Hexarelin's appetite stimulation appears somewhat less pronounced than GHRP-6 in some reports, which slightly contradicts the video's framing, but it is still present. Oral peptide bioavailability is a legitimate pharmacokinetic problem. Peptides are degraded by gastrointestinal proteases, and there is no published human trial establishing oral hexarelin efficacy at replacement doses.

What did they get wrong (or right)?

The mechanistic framing is mostly right. A few specifics are imprecise or unverifiable, and one framing is misleading enough to flag.

He referred to "Epimorlin" as part of the GHRP family. This appears to be a mispronunciation or conflation of ipamorelin, which is a legitimate GHRP, but "epimorlin" is not a recognized compound name. That is a minor but notable error in a video presenting as educational content.

His description of hexarelin as replacing "Ibud amorn or MK-677" is a loose oral shorthand for ibutamoren, the non-peptide GHS-R1a agonist. The claim that a pharmacy is positioning oral hexarelin as a replacement for MK-677 is unverifiable from the transcript and should be treated with skepticism. MK-677 is an orally active small molecule precisely because it is not a peptide. Swapping it with an oral peptide is not a straightforward equivalency.

The GHRP plus GHRH pairing advice is genuinely accurate. Combining a secretagogue that triggers GH pulse with one that amplifies GHRH signaling does produce synergistic GH release. Alba et al. (1994, Journal of Clinical Endocrinology and Metabolism) demonstrated this combination effect in vivo. That is a point where the creator deserves credit.

What should you actually know?

Hexarelin is a research-stage peptide. It is not FDA-approved for any indication, and human clinical data is limited mostly to short-term GH stimulation studies. Anyone using it is doing so outside an approved framework, which carries real uncertainty.

A few things the video does not address but matter clinically: hexarelin shows tachyphylaxis, meaning GH response diminishes with repeated dosing faster than with ipamorelin or GHRP-2 (Ghigo et al., 1994, Journal of Clinical Endocrinology and Metabolism). That is a practical limitation for anyone considering extended use. The CD36 receptor activity also means hexarelin has cardiovascular signaling effects that are not present with other GHRPs, and those effects are not fully characterized in humans. The creator's confidence in injectable hexarelin as a "great peptide" is not matched by a robust human safety database. The FDA's 2023 and 2024 actions restricting compounded peptides have left the legal and supply status of hexarelin genuinely unclear in the United States, as he acknowledges. Pairing peptides without clinical oversight, regardless of mechanistic logic, is not something a regulated telehealth context would recommend without individualized assessment.